Emerging research suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may offer a promising step forward for body management . Initial patient trials have shown substantial decreases in abdominal tissue, potentially surpassing other weight-loss treatments. Despite this, additional study is ne